---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-026659"
form_type: "8-K"
ticker: "BNTC"
cik: "0001808898"
company_name: "Benitec Biopharma Inc."
filed_at: "2025-02-14T23:59:59+00:00"
generated_at: "2026-05-26T21:32:22.092528+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Benitec Biopharma reports Q2 FY2025 net loss of $7.4M, cash at $78.3M; five patients treated with BB-301 in Phase 1b/2a

## Summary
- Net loss $7.4M ($0.33/sh) vs $6.8M ($2.64/sh) year ago; basic shares rose from 2.6M to 22.1M on warrant exercises.
- Cash and equivalents $78.3M at Dec 31, 2024, up from $50.9M; includes $39.5M from warrant exercises.
- G&A expenses $3.5M (up from $1.8M); R&D flat at $5.1M; total operating expenses $8.6M.
- Fifth subject safely treated with low-dose BB-301 in OPMD study; sixth subject expected in Q2 2025.
- Interim clinical data to be presented in late-breaking oral at MDA conference on March 19, 2025.

## SEC filing metadata
- accession: 0001193125-25-026659
- form_type: 8-K
- ticker: BNTC
- cik: 0001808898
- company_name: Benitec Biopharma Inc.
- filed_at: 2025-02-14T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1808898/000119312525026659/0001193125-25-026659-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1808898/000119312525026659/d877190d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-026659
- JSON: https://secwatch.observer/filing/0001193125-25-026659.json
- Plain text: https://secwatch.observer/filing/0001193125-25-026659.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.